<?xml version='1.0' encoding='utf-8'?>
<document id="16645869"><sentence text="Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes."><entity charOffset="21-48" id="DDI-PubMed.16645869.s1.e0" text="medroxyprogesterone acetate" /></sentence><sentence text="Medroxyprogesterone acetate (MPA), frequently used in contraception and chemotherapy, was involved in a report of drug-drug interaction (DDI) when co-administrated with phenytoin, doxifluridine and cyclophosphamide"><entity charOffset="0-27" id="DDI-PubMed.16645869.s2.e0" text="Medroxyprogesterone acetate" /><entity charOffset="29-32" id="DDI-PubMed.16645869.s2.e1" text="MPA" /><entity charOffset="169-178" id="DDI-PubMed.16645869.s2.e2" text="phenytoin" /><entity charOffset="180-193" id="DDI-PubMed.16645869.s2.e3" text="doxifluridine" /><entity charOffset="198-214" id="DDI-PubMed.16645869.s2.e4" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e0" e2="DDI-PubMed.16645869.s2.e0" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e0" e2="DDI-PubMed.16645869.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e0" e2="DDI-PubMed.16645869.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e0" e2="DDI-PubMed.16645869.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e0" e2="DDI-PubMed.16645869.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e1" e2="DDI-PubMed.16645869.s2.e1" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e1" e2="DDI-PubMed.16645869.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e1" e2="DDI-PubMed.16645869.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e1" e2="DDI-PubMed.16645869.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e2" e2="DDI-PubMed.16645869.s2.e2" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e2" e2="DDI-PubMed.16645869.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e2" e2="DDI-PubMed.16645869.s2.e4" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e3" e2="DDI-PubMed.16645869.s2.e3" /><pair ddi="false" e1="DDI-PubMed.16645869.s2.e3" e2="DDI-PubMed.16645869.s2.e4" /></sentence><sentence text=" In order to clarify the mechanism of such interaction, an in vitro study was undertaken to evaluate MPA's potential to inhibit cytochrome P450 (CYP) enzymes"><entity charOffset="101-116" id="DDI-PubMed.16645869.s3.e0" text="MPA" /></sentence><sentence text="" /><sentence text="Inhibitory effects of MPA on seven CYPs, including CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2D6, CYP2E1 and CYP3A4, were conducted in human liver microsomes"><entity charOffset="22-24" id="DDI-PubMed.16645869.s5.e0" text="MPA" /></sentence><sentence text=" Time- and NADPH-dependent inhibitions were also tested" /><sentence text=" DDI potential was predicted according to the [I]/K ( i ) value" /><sentence text="" /><sentence text="MPA was found to inhibit CYP2C9 and CYP3A4; half inhibition concentration (IC(50)) was 16"><entity charOffset="0-2" id="DDI-PubMed.16645869.s9.e0" text="MPA" /></sentence><sentence text="1 microM and 31" /><sentence text="5 microM, respectively" /><sentence text=" Slight inhibition was observed on CYP1A2, CYP2A6, CYP2C8 and CYP2D6 with IC(50) of more than 100 microM" /><sentence text=" MPA exhibited activation rather than inhibition on CYP2E1"><entity charOffset="1-3" id="DDI-PubMed.16645869.s13.e0" text="MPA" /></sentence><sentence text=" Further study revealed that MPA showed a noncompetitive inhibition on CYP2C9 and a competitive inhibition on CYP3A4 with K ( i ) of 9"><entity charOffset="29-31" id="DDI-PubMed.16645869.s14.e0" text="MPA" /></sentence><sentence text="0 microM and 36 microM, respectively" /><sentence text=" In addition, MPA was not a mechanism-based inhibitor to any of seven isoforms tested"><entity charOffset="14-16" id="DDI-PubMed.16645869.s16.e0" text="MPA" /></sentence><sentence text=" By using predicted concentration of MPA in liver, [I]/K ( i ) was estimated to be 0"><entity charOffset="37-39" id="DDI-PubMed.16645869.s17.e0" text="MPA" /></sentence><sentence text="24 and 0" /><sentence text="06 for CYP2C9 and CYP3A4, respectively" /><sentence text=" The concentration of phenytoin co-administrated with MPA was calculated to increase by 24%"><entity charOffset="22-31" id="DDI-PubMed.16645869.s20.e0" text="phenytoin" /><entity charOffset="54-62" id="DDI-PubMed.16645869.s20.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.16645869.s20.e0" e2="DDI-PubMed.16645869.s20.e0" /><pair ddi="false" e1="DDI-PubMed.16645869.s20.e0" e2="DDI-PubMed.16645869.s20.e1" /></sentence><sentence text="" /><sentence text="Based on our results, MPA can possibly cause clinically relevant DDI via the inhibition of CYP2C9"><entity charOffset="22-24" id="DDI-PubMed.16645869.s22.e0" text="MPA" /></sentence><sentence text="" /></document>